# Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

> **NCT01888874** · PHASE2 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 599 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** GLPG0634
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01888874
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-17
- **Primary completion:** 2015-02-18
- **Final completion:** 2015-05-14
- **Target enrollment:** 599 (ACTUAL)
- **Last updated:** 2020-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01888874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01888874, "Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01888874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*